Palisade Bio, Inc. announced the launch of its Clinical Steering Committee (CSC) designed to provide strategic guidance over late-stage clinical program development for its lead investigational drug, LB1148. The CSC will be chaired by retired board-certified-surgeon, Dr. David Berry, who previously served as Chairman of the Board of the predecessor company, Leading BioSciences. Additional CSC members include: Mark A. Talamini, MD, Vice President of Surgery & Program Development, Northwell Health; Jerrold H. Levy, MD, Professor of Anesthesiology and Critical Care Professor of Surgery (Cardiothoracic) Duke University Hospital; Steven D. Wexner, MD, PhD, Director of the Digestive Disease Institute and Chairman of Colorectal Surgery, Cleveland Clinic Florida; Ronald Hurst, MD, Division of Surgical Oncology at The Angeles Clinic and Research Institute; Paul A. Checchia, MD, Professor of Pediatrics at Texas Children's Hospital. Palisade Bio is currently in a Phase 2 clinical trial evaluating lead drug candidate LB1148 for accelerating return of bowel function associated with gastrointestinal (GI) surgery. The PROFILE study is a randomized, double-blind, multicenter, Phase 2 trial expected to enroll 120-200 patients undergoing elective bowel resection at 11 sites across the U.S. Patients received a single oral dose of LB1148 prior to surgery. The primary endpoint is time to return of bowel function. The presence of adhesions will be assessed in patients scheduled for a second surgery withing seven months of the initial GI surgery. Before joining the CSC at Palisade Bio, Dr. Berry brought deep medical, business and board leadership to Leading BioSciences. He is a retired urologic surgeon with 36 years of experience in endoscopic and open surgical procedures. He has served as a clinical associate professor at the University of Nevada Medical School and diplomate of the American Board of Urology.